AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Hikma Pharmaceuticals PLC
Video analysis: HKMPF
All videosNo video analysis for this stock yet. Request one from our team.
News: HKMPF
Panmure Liberum raises Hikma target price to 1,900p
Panmure Liberum has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) from 1,600p to 1,900p, saying the drugmaker's strong first-half results support further upside in its shares. The broker said Hikma's recent interim results were reassuring, with the only surprises coming on the upside and beats reported across the business.
Jefferies lifts Hikma target as CMO deal underpins growth story
Jefferies has raised its price target on Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,025p from 1,870p, pointing to the expanding contract manufacturing business as the source of the upgrade. The 'buy' rating is unchanged, with the new target implying 24% upside from Tuesday's share price of 1,633p (flat).
Citi sees Hikma discount as unwarranted after upgrade to forecasts
Citi has raised its estimates for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) following stronger-than-expected half-year results, arguing that the FTSE 100 drugmaker's valuation discount is no longer justified. Ephrem Ravi reiterated a buy rating and set a new price target of £18.70.
Hikma boost as broker raises price target
Deutsche Bank has raised its target price for Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) to 2,050p from 1,950p, reiterating its 'buy' rating on the FTSE 100 drugmaker. Kane Slutzkin said Hikma delivered a substantial beat at the half-year stage, driven primarily by the branded division, yet left full-year guidance largely unchanged.
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel...
Hikma jumps 10% as brokers point to profit beat and undemanding rating
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) shares rose 10% to 1,721p after first-half results came in ahead of expectations on profits, with both Peel Hunt and Stifel keeping buy ratings. The scale of the beat is the story.
Hikma and Fresenius best positioned from Trump's generic drug tariffs, says Citi
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) and Fresenius Medical Care (NYSE:FMS) could emerge as relative winners from Donald Trump's proposed tariffs on generic drugs because of their extensive US manufacturing operations, according to Citi. The US president this week announced plans to impose a 100% tariff on imported generic medicines from August 2028, rising to 200% a year later.
Hikma recovery story still has further to run after recent rally, says Panmure
Hikma Pharmaceuticals PLC (LSE:HIK, OTC:HKMPF) has already rebounded 30% from its lows but Panmure Liberum believes the generic drugmaker still offers upside if it can rebuild investor confidence following last year's profit warning. The broker retained its 'buy' rating and 1,600p price target ahead of the FTSE 100 group's interim results on 6 August, arguing the shares are "no longer oversold but still a good recovery story".
